Neonc Technologies Holdings, Inc. (NTHI) · Nov 3, 2026 · Other events

NeOnc SNO data posters set, but no new results yet

No new info

NeOnc’s SNO announcement sets two NEO100 and NEO212 data presentations, but the 8-K contains no new clinical results.

NeOnc is a clinical-stage CNS biotech advancing intranasal NEO100 through Phase 2 work and oral NEO212 toward Phase 2 development. This filing is a catalyst notice, not a clinical readout. It says data from both programs will be presented at the Society for Neuro-Oncology meeting on November 13, but provides no efficacy, safety, or statistical results. 〔0〕

The headline language is not the evidence. The NEO100 poster title references “durable radiographic remission and prolonged survival,” while the NEO212 title refers to “early signals of activity,” but those are presentation titles rather than disclosed results; the release itself reiterates that both programs remain investigational and that safety and efficacy have not been established. 〔1〕 〔2〕 The presentation schedule was already publicly announced on November 2, 2026, so the November 3 8-K mainly formalizes information the market already had.

Bottom line: This keeps an important clinical catalyst on the calendar but does not change the underlying business story today. The meaningful update arrives with the actual poster data on November 13, not with this filing itself.

What to watch next

SNO poster presentations, November 13, 2026

Original filing on SEC EDGAR

More Neonc Technologies Holdings, Inc. news

NeOnc SNO data posters set, but no new results yet | NTHI Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.